Congenica chosen to provide clinical decision software to NHS Genomic Medicine Service

Image of London Parliament
NHS’ Genomic Medicine Service began mobilizing earlier this month, with a network that will include laboratory hubs spread out across the country. (Avanti)

Congenica has been tapped by Genomics England to provide clinical decision support services for the NHS Genomic Medicine Service, which aims to make genetic testing a routine element of delivering healthcare.

The multiyear contract will employ Congenica’s Sapientia genome interpretation software platform.

“By working with Congenica from the start of the 100,000 Genomes Project, we’ve been able to provide high quality variant interpretation of genome sequences to the NHS, helping deliver benefits to patients at scale,” Genomics England Chief Executive John Mattick said in a statement.

The MedTech Conference

The MedTech Conference: September 23-25, Boston, MA

With over 3,000 attendees from 35 countries, The MedTech Conference features world-class plenary speakers, cross-cutting educational programming and business development opportunities. This is a prime opportunity to network, conduct business and share insights with medtech leaders. Register before July 26th and save $200!

NHS’ genomic service began mobilizing earlier this month, with a network that will include genomic laboratory hubs spread out across the country. Initially, patients with cancer and rare and inherited diseases will be able to access genomic testing, before it opens to other populations.

“Genomics England and the NHS have done extraordinary work in building the foundations for the Genomic Medicine Service,” said Congenica CEO David Atkins, Ph.D., describing the initiative as the world’s first of its kind.

RELATED: IQVIA and Genomics England to launch real-world research platform as the U.K. looks to boost cancer diagnostics

Sapientia was validated on approximately 10,000 genomes during Genomics England’s 100,000 Genomes Project, with Congenica scientists using the platform to analyze patients’ genetic code and produce actionable clinical reports.

The 100,000 Genomes Project is expected to reach its goal before the end of 2018; as of Oct. 1, the program has sequenced 87,231 whole genomes.

Suggested Articles

Eisai showed correlations between amyloid biomarkers in the blood and cerebrospinal fluid, bringing it closer to a simple blood test for Alzheimer’s.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.